{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:43Z","timestamp":1787732383465,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG8M0851"],"award-info":[{"award-number":["CMRPG8M0851"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG8N0681"],"award-info":[{"award-number":["CMRPG8N0681"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bj.2026.100976","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:27:37Z","timestamp":1775809657000},"page":"100976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radium-223 Treatment Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer: A Taiwan-Japan Collaborative Cohort Study"],"prefix":"10.1016","author":[{"given":"Hao Lun","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kawaguch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Ta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin Lun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2026.100976_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.100976_bib2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bj.2026.100976_bib3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00259-019-4261-y","article-title":"Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice","volume":"46","author":"Dizdarevic","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bj.2026.100976_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032671","article-title":"Treatment outcomes with radium-223 in docetaxel-naive versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan","volume":"102","author":"Chiang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bj.2026.100976_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s13139-022-00760-8","article-title":"Outcomes and Factors Associated with Completion of Radium-223 Therapy","volume":"56","author":"Liu","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.bj.2026.100976_bib6","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.clgc.2016.08.015","article-title":"Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy","volume":"15","author":"McKay","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.bj.2026.100976_bib7","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00345-021-03639-z","article-title":"A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer","volume":"39","author":"Miyoshi","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.bj.2026.100976_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bj.2026.100976_bib9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/iju.15008","article-title":"Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study","volume":"29","author":"Kawahara","year":"2022","journal-title":"Int J Urol."},{"key":"10.1016\/j.bj.2026.100976_bib10","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bj.2026.100976_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","article-title":"Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial","volume":"73","author":"Parker","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.bj.2026.100976_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0000000000000528","article-title":"Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection","volume":"42","author":"Den","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bj.2026.100976_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10147-020-01850-3","volume":"26","author":"Uemura","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.bj.2026.100976_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/pros.23180","article-title":"Chemotherapy following radium-223 dichloride treatment in ALSYMPCA","volume":"76","author":"Sartor","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.bj.2026.100976_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10147-017-1176-0","article-title":"Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer","volume":"23","author":"Matsubara","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.bj.2026.100976_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clgc.2016.07.027","article-title":"Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial","volume":"15","author":"Vogelzang","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.bj.2026.100976_bib17a","volume":"92","author":"Frantellizzi","year":"2020"},{"key":"10.1016\/j.bj.2026.100976_bib17b","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1002\/cam4.3459","article-title":"Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer","volume":"9","author":"Hashimoto","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.bj.2026.100976_bib18","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1002\/cam4.5262","article-title":"Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study","volume":"12","author":"Hyvakka","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.bj.2026.100976_bib19","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-020-63302-2","article-title":"Clinical aspects of mCRPC management in patients treated with radium-223","volume":"10","author":"Rizzini","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.bj.2026.100976_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333\/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.bj.2026.100976_bib21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41391-025-00969-6","article-title":"Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States","volume":"28","author":"Raval","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.bj.2026.100976_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.10.020","article-title":"Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial","volume":"71","author":"Parker","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.bj.2026.100976_bib23","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.100976_bib24","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1038\/s41598-021-86033-4","article-title":"Pretreatment PSA levels affects the completion rate of Ra-223 treatment","volume":"11","author":"Utsumi","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.bj.2026.100976_bib25","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2026.100976_bib26","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.bj.2026.100976_bib27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417026000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:23Z","timestamp":1787729603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417026000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"alternative-id":["S2319417026000326"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2026.100976","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radium-223 Treatment Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer: A Taiwan-Japan Collaborative Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2026.100976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"100976"}}